top of page

IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year

  • blonca9
  • Oct 11, 2024
  • 1 min read

Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

​

​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page